Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
Cancer Research, Volume 50, No. 13, Year 1990
Notification
URL copied to clipboard!
Description
Previous studies have suggested that overexpression of HER-2/neu oncogene occurs in 15–40% of breast cancers and that overexpression is associated with poor prognosis. In the present report, we have used an immunohistochemical technique involving a monoclonal antibody specifically reactive with the external domain of HER-2/neu to study expression of HER-21neu in frozen sections of normal ovary and advanced epithelial ovarian cancer. The intensity of staining for HER-2neu was always moderate or less (0–2+) in normal ovarian epithelium. Among 73 ovarian cancers, 50 (68%) had staining similar to that for normal ovarian epithelium (0–2+) while 23 (32%) stained heavily (3+). Survival of the 23 patients with high HER-21neu expression (median, 15.7 months) was significantly worse (P = 0.001) than that of the 50 patients (median, 32.8 months) with normal HER-21neu expression. In addition, patients whose tumors had high HER-21neu expression were significantly less likely to have a complete response to primary therapy (P < 0.05) or have a negative second-look laparotomy when serum CA 125 levels were normal preoperative (P < 0.05). These findings suggest that HER-2/neu deserves further evaluation as a prognostic marker in epithelial ovarian cancer. © 1990, American Association for Cancer Research. All rights reserved.
Authors & Co-Authors
Berchuck, Andrew W.
United States, Durham
Duke University Medical Center
United States, Durham
University Medical Center
Whitaker, R.
United States, Durham
Duke University Medical Center
Olt, G.
United States, Durham
Duke University Medical Center
Soper, J. T.
United States, Durham
Duke University Medical Center
Clarke-Pearson, D. L.
United States, Durham
Duke University Medical Center
Kamel, A.
United States, Durham
Duke University Medical Center
Egypt, Cairo
Ain Shams University
Bast, Robert C.
United States, Durham
Duke University Medical Center
United States, Durham
Duke Cancer Institute
Kerns, B.
United States, Durham
Duke University Medical Center
Kinney, R.
United States, Durham
Duke University Medical Center
Dodge, R.
United States, Durham
Duke University Medical Center
Marks, P.
United States, Tarrytown
Siemens Healthcare Diagnostics Inc.
McKenzie, S.
United States, Tarrytown
Siemens Healthcare Diagnostics Inc.
Yin, S.
United States, Tarrytown
Siemens Healthcare Diagnostics Inc.
Statistics
Citations: 13
Authors: 13
Affiliations: 5
Identifiers
ISSN:
00085472
e-ISSN:
15387445
Research Areas
Cancer